Identification of novel selective P2Y6 receptor antagonists by high-throughput screening assay.
Life Sci
; 180: 137-142, 2017 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-28527783
ABSTRACT
AIMS:
The P2Y6 nucleotide receptor is widely involved in inflammatory responses, and is a promising molecular target for the treatment of inflammatory diseases. Although several P2Y6 receptor antagonists have been developed and evaluated thus far, none has successfully been developed into a therapeutic drug. In this study, we explored new promising compounds that inhibit the human P2Y6 receptor. MAINMETHODS:
High-throughput screening (HTS) was used to study the effects of various compounds on human P2Y6 receptors expressed in 1321N1 human astrocytoma cells by monitoring intracellular Ca2+ concentration ([Ca2+]i) levels using an FDSS7000 real-time fluorescence detector. IL-8 concentration was measured by enzyme-linked immunosorbent assay. KEYFINDINGS:
Among structurally diverse chemical libraries totalling 141,700 compounds, 43 compounds with an inhibitory activity against the P2Y6 receptor were identified. Further studies using a dose-response assay, receptor selectivity assay, and chemokine measurement assay revealed the selective P2Y6 receptor inhibitor TIM-38, which inhibited UDP-induced [Ca2+]i elevation in a dose-dependent manner. TIM-38 had an IC50 value of 4.3µM and inhibited P2Y6 without affecting the response induced by four other human P2Y or muscarinic receptors. In addition, TIM-38 inhibited UDP-induced interleukin-8 release in a dose-dependent manner without affecting releases caused by other stimulus such as interleukin-1ß or tumour necrosis factor-α. Analyses of TIM-38 derivatives revealed that the nitro moiety is vital to P2Y6 receptor inhibition.SIGNIFICANCE:
TIM-38 acts as a novel structural antagonist of P2Y6 receptor and may be a good lead compound for developing a P2Y6 receptor-targeted anti-inflammatory drug.Palavras-chave
Compound 1 (6-bromo-3-nitro-2-(trifluoromethyl)-2H-chromene, PubChem CID: 11681366); Compound 2 (2-(4-chlorophenyl)-3-nitro-2H-chromene, PubChem CID: 3774501); Compound 3 (2-(4-methoxyphenyl)-3-nitro-2H-chromene, PubChem CID: 2732134); Compound 4 (3-nitro-2-phenyl-2H-chromene, PubChem CID: 42450); High-throughput screening; Interleukin-8; P2Y(6) receptor antagonist; TIM-38 (3-nitro-2-(trifluoromethyl)-2H-chromene, PubChem CID: 16762479)
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Desenho de Fármacos
/
Receptores Purinérgicos P2
/
Ensaios de Triagem em Larga Escala
/
Antagonistas do Receptor Purinérgico P2Y
/
Anti-Inflamatórios
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Limite:
Humans
Idioma:
En
Revista:
Life Sci
Ano de publicação:
2017
Tipo de documento:
Article